AUTHORS
Frederick Ian Lemaistre, MD, MPH, Kathryn Yarkony2, Alexander Joseph Ambinder, MD, MPH3, Christian Burris Gocke, MD, PhD4, Heather J. Symons, MD5, Amy DeZern, MD, MHS6, Kenneth R Cooke, MD7, Javier Meade8, Ravi Varadhan, PhD9, Richard John Jones, MD10
AFFILIATIONS
1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
2 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
3 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
4 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
5 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
6 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
7 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
8 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
9 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
10 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
ABSTRACT
Background: Mismatched donor platforms have expanded access to allogeneic blood and bone marrow transplantation (alloBMT), providing patients near universal access often with multiple viable donor options. Thus, identifying optimal donors has become increasingly important. Existing observational studies on the subject assess outcomes only among patients who successfully proceeded to alloBMT, leaving earlier, donor-related barriers, logistical challenges, and costs unexamined.
Methods: We conducted a retrospective analysis of patients with hematologic malignancies who underwent alloBMT with post-transplant cyclophosphamide (PTCy) at a single institution. We evaluated overall survival (OS) in all patients between 2018 and 2025 by donor type. We then assessed donor-related transplant delays or cancellations, as well as total transplant and graft charges by donor type in 374 consecutive patients transplanted between January 1, 2024, and December 31, 2025.
Results: In 1298 patients, OS did not differ by donor-type. Compared to related donors (RDs), unrelated donor (URD) transplants in 2024-2025 were more likely to experience a donor-related delay (26% vs 2.2 %, p<0.001). Both URDs (OR 14.3, 95% CI 5.08 – 49.6; p <0.001) and Black patients (OR 2.98, 95% CI 1.27-6.66; p = 0.010) had significantly increased odds of donor-related delays on univariable regression. Charges for URD transplants were significantly higher than RD ($184,036 vs $150,716 p <0.001), driven by graft acquisition charges.
Conclusions: Using PTCy, survival outcomes were comparable across donor types. Related donors were more likely to advance to a timely donation, reflecting higher availability, stronger personal commitment, and fewer logistical barriers compared with unrelated donors.
DISCLOSURES
Frederick Ian Lemaistre, MD, MPH: No relevant conflicts of interest to declare.